Studies such as SUSTAIN, PIONEER, and STEP highlight its superiority compared to other GLP-1 receptor agonists and anti-obesity drugs in [50]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.